STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo shows promise against tough bile duct cancer
Disease control OngoingThis phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Tailored radiation beams aim to boost liver cancer treatment
Disease control OngoingThis trial tests whether giving liver cancer patients a personalized dose of radiation (Yttrium-90) can improve tumor shrinkage compared to standard dosing. The study includes 42 adults with advanced liver cancer that cannot be removed by surgery. Researchers use special scans to…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Immunotherapy duo after radiation shows promise for untreatable liver cancer
Disease control OngoingThis early-stage trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation treatment can help control advanced liver cancer that cannot be removed by surgery. The study involves 25 adults with liver cancer that has spread locally.…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug cocktail aims to shrink liver tumors before surgery
Disease control OngoingThis phase 2 trial tests whether combining the targeted drug regorafenib with the immunotherapy durvalumab can shrink high-risk liver cancer before surgery. The study enrolled 4 adults with stage IB to IIIA hepatocellular carcinoma. Researchers are measuring how many patients see…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 26, 2026 14:15 UTC